Frederick Lief Ruberg, MD

Associate Professor, Medicine

Frederick Ruberg
(617) 638-8968
75 E. Newton St Collamore Building

Biography

Dr. Ruberg’s clinical and research expertise is in the field of cardiac imaging including echocardiography and cardiovascular magnetic resonance imaging (CMR). Dr. Ruberg applies imaging in research designed to facilitate improved diagnosis and management of the infiltrative cardiomyopathy cardiac amyloidosis.

Other Positions

  • Associate Professor, Radiology, Boston University School of Medicine
  • Program Director, Pilot Translational & Clinical Studies Program, Clinical and Translational Science Institute, Boston University School of Medicine
  • Active Staff Privileges, Medicine, Boston Medical Center

Education

  • University of Pennsylvania School of Medicine, MD
  • Haverford College, BA

Publications

  • Published on 1/3/2018

    Maurer MS, Ruberg FL, Weinsaft JW. More Than Meets the Eye: Time for a New Imaging Paradigm to Test for Cardiac Amyloidosis. J Card Fail. 2018 Jan 03. PMID: 29305971.

    Read at: PubMed
  • Published on 10/20/2017

    Arvanitis M, Chan GG, Jacobson DR, Berk JL, Connors LH, Ruberg FL. Prevalence of mutant ATTR cardiac amyloidosis in elderly African Americans with heart failure. Amyloid. 2017 Dec; 24(4):253-255. PMID: 29052438.

    Read at: PubMed
  • Published on 9/1/2017

    Salinaro F, Meier-Ewert HK, Miller EJ, Pandey S, Sanchorawala V, Berk JL, Seldin DC, Ruberg FL. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2017 Sep 01; 18(9):1057-1064. PMID: 27965280.

    Read at: PubMed
  • Published on 7/24/2017

    Arun M, Brauneis D, Doros G, Shelton AC, Sloan JM, Quillen K, Ruberg FL, Sanchorawala V, Varga C. The incidence of atrial fibrillation among patients with AL amyloidosis undergoing high-dose melphalan and stem cell transplantation: experience at a single institution. Bone Marrow Transplant. 2017 09; 52(9):1349-1351. PMID: 28737773.

    Read at: PubMed
  • Published on 7/13/2017

    Siddiqi OK, Ruberg FL. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med. 2018 Jan; 28(1):10-21. PMID: 28739313.

    Read at: PubMed
  • Published on 6/21/2017

    Siddiqi OK, Ruberg FL. Challenging the myths of cardiac amyloidosis. Eur Heart J. 2017 Jun 21; 38(24):1909-1912. PMID: 28444296.

    Read at: PubMed
  • Published on 3/15/2017

    Ruberg FL. Cardiac Amyloidosis: A Zebra Hiding in Plain Sight? Circ Cardiovasc Imaging. 2017 Mar; 10(3):e006186. PMID: 28298289.

    Read at: PubMed
  • Published on 3/1/2017

    Arvanitis M, Koch CM, Chan GG, Torres-Arancivia C, LaValley MP, Jacobson DR, Berk JL, Connors LH, Ruberg FL. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model. JAMA Cardiol. 2017 Mar 01; 2(3):305-313. PMID: 28196196.

    Read at: PubMed
  • Published on 3/1/2017

    Di Carli MF, Davidoff R, Beerbaum P, Dorbala S, Gillam LD, Hoffmann U, Raman SV, Ruberg FL. Editor's Note. Circ Cardiovasc Imaging. 2017 Mar; 10(3). PMID: 28289023.

    Read at: PubMed
  • Published on 3/1/2017

    Arvanitis M, Simon S, Chan G, Fine D, Beardsley P, LaValley M, Jacobson D, Koch C, Berk JL, Connors LH, Ruberg FL. Retinol binding protein 4 (RBP4) concentration identifies V122I transthyretin cardiac amyloidosis. Amyloid. 2017 Mar; 24(sup1):120-121. PMID: 28434357.

    Read at: PubMed

View 54 more publications: View full profile at BUMC

View all profiles